This Medudy course is a video tutorial for physicians on the topic of “Long-term management and handling of side effects associated with lorlatinib—weight gain.”
In this video, Dr. Carolin Groß-Ophoff, senior physician in hematology and oncology at the City of Cologne Hospitals, discusses the ALK tyrosine kinase inhibitor lorlatinib, which is approved for the treatment of advanced, ALK-positive non-small cell lung cancer. Due to its good efficacy in the central nervous system, lorlatinib is recommended as the preferred first-line therapy in current guidelines. At the same time, side effects frequently occur during treatment; in particular, weight gain is commonly observed. With careful counseling of patients and their families, this is manageable in most cases.
Lifestyle adjustments are often sufficient, and with structured side-effect management and monitoring during treatment, pharmacological strategies are largely unnecessary.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was developed with the kind support of Pfizer.
By the end of this training session, you will be familiar with:
– the key facts about lorlatinib
– the key findings of the CROWN study
– weight gain as a common side effect of treatment
– options for long-term management involving patients and their families
